Estrella Immunopharma Hit With Second Nasdaq Delisting Notice — Now Fails Market Value Rule
ESLA is trading near its 52-week low of $0.585 (9.5% above the low).
Summary
A second Nasdaq delisting notice hit Estrella Immunopharma for failing the $35 million minimum market value requirement, adding to its existing bid-price deficiency and deepening its listing crisis.
Key Events · Legal and Risk Events · ESLA
-
Second Nasdaq Delisting Notice
Nasdaq notified the company on September 1, 2026, that its MVLS fell below $35 million for 30 consecutive business days (July 21 – August 31, 2026), violating Listing Rule 5550(b)(2).
-
Fails All Alternative Listing Standards
The company also fails the stockholders' equity standard (below $2.5 million) and the net income standard (below $500,000), leaving no alternative path to continued listing.
-
Compliance Deadline Set
The company has 180 calendar days, until March 1, 2027, to regain MVLS compliance by closing at or above $35 million for at least 10 consecutive business days.
-
Compounding Listing Crisis
This is the second delisting notice in three weeks, following the August 21, 2026 bid-price deficiency notice, and comes amid going-concern doubt with only $0.1 million in cash.
Analysis · ESLA · Life Sciences
A second Nasdaq delisting notice landed on September 1, 2026, this time for failing the minimum market value of listed securities (MVLS) requirement. The company's MVLS fell below $35 million for 30 consecutive business days, and it also fails the alternative equity and net income standards. This compounds the prior bid-price deficiency disclosed on August 21, 2026, and comes just weeks after the Q2 10-Q revealed only $0.1 million in cash against $9.3 million in current liabilities. The company now faces two separate compliance deadlines and must regain MVLS compliance by March 1, 2027, or face delisting proceedings. With a market cap of roughly $28 million and a stock price of $0.64, the path to regaining compliance is severely constrained by the company's distressed financial position.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.8% of the 571 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESLA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.9M. The 52-week trading range was $0.59 to $3.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.